User login
Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.
Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).
Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.
Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.
Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.
Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.
Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).
Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.
Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.
Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.
Key clinical point: Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.
Major finding: Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).
Study details: The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.
Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.
Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.